To better understand how carcinogenesis-associated ECMs may participate in BZDR-promoted BRCA advancement, we analyzed these 1516 ECMs in the TCGA database and examined 1067 primary tissues, including 189 Triple negative breast cancer (TNBC) and 878 non-TNBC (including HER2, LumA, LumB, normal-like). The gene discussed is ERBB2; the disease is triple-negative breast carcinoma.